Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Presendin for Idiopathic Intracranial Hypertension
NCT05347147Phase 3Terminated
- Sponsor
- Invex Therapeutics Ltd
- Start
- Nov 2022
- Primary completion
- Sep 2023
- Modality
- Peptides, Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in idiopathic intracranial hypertension (IIH) comparing Presendin with Placebo (2 arms). Primary endpoint: Change in Intracranial Pressure at 24 weeks. Started Nov 2022; status: terminated.
02
Drugs
Presendin
03
Conditions
idiopathic intracranial hypertension (IIH)
Beyond the preview
Go deeper on NCT05347147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05347147.